We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
ESTRO
Menu
  • Corporate Members
  • E-Library
  • Twitter
  • Linked In
  • Facebook
  • Instagram
  • Join
  • MyESTRO
Search Opener
  • About ESTRO
  • Membership
  • School
  • Workshops
  • Congresses
  • Science
  • Education
  • Advocacy
  • Corporate Members
  • E-Library
  1. Home
  2. About ESTRO
  3. Newsroom
  4. Newsletter
  5. Read it before your patients

Achieve recognition of all radiotherapy professions

Read it before your patients
  • 09/12/2025

    Definitions of, Advances in, and Treatment Strategies for Breast Cancer Oligometastasis

  • 04/12/2025

    Efficacy of Stereotactic Ablative Body Radiotherapy (SABR) in uncommon subtypes of primary kidney cancer: An analysis from the International Radiosurgery Oncology Consortium of the Kidney.

  • 04/12/2025

    European Study of Prostate Cancer Screening — 23-Year Follow-up

  • 01/12/2025

    Salvage Metastasis-Directed Therapy Versus Elective Nodal Radiotherapy for Oligorecurrent Nodal Prostate Cancer Metastases (PEACE V-STORM): A Phase 2, Open-Label, Randomised Controlled Trial

  • 27/11/2025

    Health-Related Quality of Life in Patients Treated for Nonmetastatic Muscle-Invasive Bladder Cancer: Radical Cystectomy Versus Bladder-Preserving Therapy

  • 21/11/2025

    Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer

News Pages: 1 2 3 4 5 6 7 8 9 10
  • Newsletter 2019
  • Newsletter 2018
  • Newsletter 2017

Corner editors: Orit Person, Ever van Limbergen and Philippe Lambin.

  • Contact
  • Privacy Statement
  • Sitemap
  • Careers
  • FAQ
  • Twitter
  • Linked In
  • Facebook
  • Instagram

© The European SocieTy for Radiotherapy and Oncology. All rights reserved. ESTRO Avenue Marnix 17, 1000 Brussels . +32 477 271 125.